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drug manufacturers and the decision makers. This study reports the findings from 
a survey of pricing and reimbursement experts in Australia to gain insight into 
their attitude/opinions of RSAs from their own personal experience. Methods: 
Senior-level health economists and consultants were targeted. The survey included 
questions about responder’s demographics, the number and type of RSAs they have 
personally been involved with, and their experience and opinions about RSAs. A 
general overview of RSAs is also provided to better contextualise the survey find-
ings. Results: Ten experts participated on an anonymous basis. They in total have 
been involved in 403 submissions, and 56 RSAs of various types. Capped cost agree-
ments were most frequently employed (> 70% of all RSAs). ‘Hidden price’ is also 
frequently agreed. Respondents generally had positive attitude towards RSA (mean 
of 3 using a 1-5 scale) mainly because it can potentially benefit timeline and address 
global pricing issues. Concerns were however raised about the fact that the ‘risk’ is 
entirely borne by the industry in many cases and RSA has now become an integral 
element in the PBAC’s decision making process. ConClusions: RSA is generally 
well perceived among industry experts in Australia, whilst an increasing role of 
PBAC in defining clauses in the agreement is seen as a hurdle against productive 
involvement from the industry. The Australian model of RSA may offer a useful 
template for other jurisdictions.
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objeCtives: This study is designed to review current ‘risk-sharing’ schemes 
worldwide and in China, and further examine what kind of situations where 
‘risk-sharing’ schemes should be considered. Methods: A literature review 
was undertaken to identify existing schemes in developed countries. A review 
of released policies in China was also conducted to understand China’s current 
rules of practice. Cases studies were established for detailing agreement structure 
and potential impact on payers and industry. Results: Risk-sharing schemes are 
introduced to the market in the context of fast growing health care cost and uncer-
tain drug values. Nearly almost all of China’s scheme practices are financial-based 
agreements and don’t integrate drug’s real world performance. Unlike mature 
market, risk-sharing agreement in China is more often applied to established 
products rather than newly-entered innovative drugs. A typical successful agree-
ment in China has several must-have factors, including discounted drug price, 
purchase/free drug package and charity program. When considering a sustainable 
win-win risk-sharing scheme, a company must be very determined and assess its 
product carefully to decide whether the disease is in a high priority and there are 
currently few effective treatments; where policies can be leveraged and opportuni-
ties can be created for negotiation; whether strong lobbying message and product 
value proposition can be developed to meet the interests of the stakeholders; 
whether proposed scheme (price and additional service) can substantially lower 
health service cost as well as to enhance reimbursement; whether management 
team can ensure well-functioning operational capabilities for legal, administra-
tive and delivery support. ConClusions: With more innovative drugs being 
introduced to China market; ‘risk-sharing’ schemes will become more popular 
as national reimbursement drug list cannot immediately cover the increasing 
cost. Global experience also suggests there is a trend that ‘risk-sharing’ agree-
ment will be more often considered as a market access strategy for new products 
in the future.
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In the last three decades, evidence-based medicine (EBM) has been the driving 
force in shaping guidelines and clinical decision making in screening, prevention 
and treatment of diseases. Evidence review, evidence grading and meta-analysis 
of trials are standardized and routinely conducted. However, recent technological 
developments have significant impacts on future directions of EBM. With recent 
advances in health information technology, electronic medical records (EMRs), 
proteomics and genomics, clinical evidence has become increasingly abundant 
and diverse. At the same time, the inputs into medical decision making have also 
become increasingly complex. Model Based Medicine (MBM) has recently emerged 
as a framework to address the above challenges. MBM is the use of large-scale 
integrated physiology and pathology-driven mathematical models to translate and 
to synthesize existing evidence and medical knowledge into a unified framework, 
which will then be used to support clinical decision making at individual patient 
level. MBM not only incorporates all available evidence and most up-to-date 
understanding of diseases but also account for uncertainties in data and gaps in 
knowledge. MBM serves as an interface between evidence and physicians, allow-
ing rapid extraction of quantitative, robust and already synthesized information 
for customized clinical decision making. The decisions can be optimized not only 
based on the therapeutic efficacy of health interventions, current health status 
of patients but also patient’s health behavior (e. g. past likelihood to comply with 
treatment recommendations) and preferences. Based on our recent experience at 
Archimedes, I will present several case studies to illustrate the power of MBM in 
leveraging data from EHR and other data sources to support decision making at 
both population and individual level. I will also speak about the scientific and tech-
nical challenges faced by MBM and our strategy in addressing these challenges, 
including developments of standardized and automatic tools for data integration 
and synthesis, model calibration and validation, uncertainty quantification and 
optimal design for model-physician interface.
follow or they do not have customized service standards. Moreover, basing on the 
result, medical staffs have no common awareness what standards they must follow 
for their services, except awareness of treatment and diagnosis; there is insufficient 
information about service standards. ConClusions: One third of organizations 
attended in surveys operates their operations without the organization’s service 
standards. Service standards of an organization are developed by Medical directors, 
Quality department and Professional council. Service standards of organizations are 
not approved, there is no any control to implement service standards, or the service 
standards are inappropriate and no unfavorable environment to implement service 
standards. Even the control on “Common operation standards”’s implementation is 
good, no unfavorable environment to implement the standard. Moreover registration 
of mistakes related to “Common operation standards” is insufficient, measures and 
warnings to improve the low indication of mistakes are not taken well.
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objeCtives: Priority setting in the allocation of new medical interventions is 
increasingly based on formulated values. Before drafting the new medical service 
items and fee schedule, the National Health Insurance Act of Taiwan identifies 
four prioritizing rules -human health, medical ethics, cost-effectiveness, and the 
finances of the Insurance respectively to compliance with. Our study objectives 
are to compare the policy makers’ actual value preferences with these four official 
formulated principles and to guide the Ministry of Health and Welfare in Taiwan 
in the priority setting of new medical interventions. Methods: We used a mul-
ticriteria decision analytical framework. In total 65 respondents participated in 
a discrete choice experiment to weigh their relative importance of six selected 
policy criteria for priority setting. Regression analysis was used to rank order a set 
of new recently adopted medical interventions on the basis of these criteria and 
related to weights. Results: Policymakers considered severity of disease, people 
of middle-age, cost effectiveness as the most important criteria for priority setting 
of interventions, followed by low budget impact. Signs of coefficients of many ben-
eficiaries and large individual benefits did not have the expected direction. Certain 
interventions in HIV Ag/Ab test, HLA-B 1502 gene typing, HCV Genotyping Test and 
orthopedic surgery rank highest. Cochlear implant ranks 12th out of 22 medical 
interventions. ConClusions: Policy makers’ values are partially in agreement with 
principles formulated in National Health Insurance laws. Multi-criteria decision 
approaches may provide a tool to guide explicit allocation decisions.
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objeCtives: Having maintained close association with China through the ages, a 
number of traditional Chinese medicine hospitals have prevailed in South Korea 
despite abundance of western medicines. Given this prevalence of herbal medicinal 
therapy and the increasing health care expenditure, the purpose of this research is to 
explore the feasibility of formally establishing guidelines and conducting pharmaco-
economic evaluations for coverage selection of traditional Chinese medicine from the 
perspective of decision makers in the Republic of Korea. Methods: Research was 
conducted, using qualitative telephone and email-based interviews with individuals 
involved in Health Insurance Review & Assessment Service (HIRA) and KOLs in South 
Korea in order to gain a broad range of perspectives on the topic. The interviewees 
were asked to share their opinions on the significance and viability of developing for-
mal guidelines and performing economic evaluations for traditional herbal medicines. 
Moreover, they were asked to identify critical issues around applying established 
pharmacoeconomic guidelines to traditional medicinal therapy. Results: In the 
primary research, the majority of interviewees agreed on the importance of conduct-
ing pharmacoeconomic evaluations for traditional medicine. They recognised that 
a great amount of herbal medicine is produced and consumed. Patients pay for this 
medicine as out-of-pocket expense, although the outcomes are not well measured 
and understood by either the government or the public. Furthermore, they acknowl-
edged that existing pharmacoeconomic guidelines may not always be appropriate 
for making coverage decisions for these herbal treatments. Finally, they expected that 
separate guidelines specifically targeted at traditional medicine may develop, but not 
in a very near future. ConClusions: Given the extensive use of herbal medicine by 
the public, using pharmacoeconomic evaluation for reimbursement decision may 
encourage patients and physicians to choose more cost effective treatments and thus 
prevent the dramatic increase in total health care expenditure without demonstrated 
improvement in health outcomes.
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objeCtives: Conditional reimbursement approval for pharmaceuticals, for exam-
ple, risk-sharing arrangement (RSA) involving price-volume agreement or various 
post-launch monitoring requirements, is becoming a standard practice in Australia, 
especially for novel treatments with high ICER and/or potentially significant budget 
impact. Uptake of RSAs are relatively slow in other jurisdictions. Efficient implemen-
tation of an RSA requires active involvement from all stakeholders, in particular, 
